Leeward Investments LLC MA Reduces Stock Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Leeward Investments LLC MA lowered its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 20.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 58,591 shares of the medical research company's stock after selling 15,179 shares during the period. Leeward Investments LLC MA owned about 0.07% of Laboratory Co. of America worth $13,094,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Industrial Alliance Investment Management Inc. acquired a new position in shares of Laboratory Co. of America during the second quarter valued at about $27,000. Horizon Bancorp Inc. IN bought a new position in Laboratory Co. of America in the 3rd quarter worth about $29,000. Pathway Financial Advisers LLC purchased a new position in Laboratory Co. of America during the 1st quarter valued at about $30,000. Innealta Capital LLC bought a new stake in shares of Laboratory Co. of America during the second quarter valued at about $32,000. Finally, Family Firm Inc. purchased a new stake in shares of Laboratory Co. of America in the second quarter worth about $37,000. 95.94% of the stock is owned by institutional investors.

Laboratory Co. of America Trading Up 2.0 %

Laboratory Co. of America stock traded up $4.72 during mid-day trading on Thursday, reaching $239.10. 718,137 shares of the company traded hands, compared to its average volume of 665,647. The firm's 50 day moving average price is $222.59 and its 200 day moving average price is $213.85. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $240.39. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30. The firm has a market capitalization of $20.00 billion, a price-to-earnings ratio of 46.41, a P/E/G ratio of 1.87 and a beta of 1.05.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. The company had revenue of $3.28 billion for the quarter, compared to analysts' expectations of $3.26 billion. During the same period in the prior year, the firm earned $3.38 earnings per share. The firm's revenue for the quarter was up 7.4% on a year-over-year basis. On average, analysts anticipate that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 annualized dividend and a dividend yield of 1.20%. Laboratory Co. of America's payout ratio is currently 55.71%.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $227.05, for a total value of $454,100.00. Following the completion of the transaction, the executive vice president now directly owns 3,670 shares of the company's stock, valued at approximately $833,273.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the company's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $227.05, for a total transaction of $454,100.00. Following the transaction, the executive vice president now directly owns 3,670 shares of the company's stock, valued at $833,273.50. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the sale, the director now owns 13,722 shares of the company's stock, valued at $3,156,060. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,000 shares of company stock valued at $4,043,950 in the last 90 days. Corporate insiders own 0.85% of the company's stock.

Analyst Upgrades and Downgrades

LH has been the topic of several research analyst reports. Barclays upped their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an "equal weight" rating in a report on Friday, October 25th. UBS Group increased their target price on Laboratory Co. of America from $260.00 to $270.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Bank of America lifted their price target on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a "buy" rating in a research note on Monday, August 5th. Jefferies Financial Group increased their price objective on Laboratory Co. of America from $245.00 to $265.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Finally, Robert W. Baird upped their target price on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $255.92.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.